Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.91
SNTA's Cash to Debt is ranked higher than
61% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. SNTA: 3.91 )
SNTA' s 10-Year Cash to Debt Range
Min: 2.39   Max: No Debt
Current: 3.91

F-Score: 2
Z-Score: -6.04
M-Score: -3.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -183.72
SNTA's ROE (%) is ranked lower than
56% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. SNTA: -183.72 )
SNTA' s 10-Year ROE (%) Range
Min: -320.7   Max: 317.48
Current: -183.72

-320.7
317.48
ROA (%) -94.74
SNTA's ROA (%) is ranked lower than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. SNTA: -94.74 )
SNTA' s 10-Year ROA (%) Range
Min: -111.95   Max: 161.7
Current: -94.74

-111.95
161.7
ROC (Joel Greenblatt) (%) -5638.06
SNTA's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. SNTA: -5638.06 )
SNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5638.06   Max: 1993.56
Current: -5638.06

-5638.06
1993.56
Revenue Growth (%) -100.00
SNTA's Revenue Growth (%) is ranked lower than
51% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. SNTA: -100.00 )
SNTA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 164.5
Current: -100

0
164.5
EBITDA Growth (%) 12.20
SNTA's EBITDA Growth (%) is ranked higher than
82% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. SNTA: 12.20 )
SNTA' s 10-Year EBITDA Growth (%) Range
Min: -29.9   Max: 158.9
Current: 12.2

-29.9
158.9
EPS Growth (%) 10.90
SNTA's EPS Growth (%) is ranked higher than
79% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. SNTA: 10.90 )
SNTA' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 166.5
Current: 10.9

-37.2
166.5
» SNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SNTA Guru Trades in Q1 2013

Jim Simons 126,400 sh (New)
Steven Cohen 250,000 sh (New)
Louis Moore Bacon 43,500 sh (New)
» More
Q2 2013

SNTA Guru Trades in Q2 2013

Paul Tudor Jones 18,600 sh (New)
Steven Cohen 2,033,004 sh (+713.2%)
Louis Moore Bacon Sold Out
Jim Simons Sold Out
» More
Q3 2013

SNTA Guru Trades in Q3 2013

Paul Tudor Jones Sold Out
Steven Cohen 2,005,800 sh (-1.34%)
» More
Q4 2013

SNTA Guru Trades in Q4 2013

Jim Simons 214,000 sh (New)
Louis Moore Bacon 115,000 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-06-30 Sold Out 0.0035%$3.68 - $7.82 $ 4.09-13%0
Jean-Marie Eveillard 2012-03-31 New Buy$4.22 - $5.66 $ 4.09-9%200000
Michael Price 2011-06-30 Sold Out 0.1%$4.45 - $6.23 $ 4.09-24%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.00
SNTA's P/B is ranked lower than
72% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. SNTA: 7.00 )
SNTA' s 10-Year P/B Range
Min: 2.91   Max: 38.2
Current: 7

2.91
38.2
EV-to-EBIT 1.40
SNTA's EV-to-EBIT is ranked higher than
97% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. SNTA: 1.40 )
SNTA' s 10-Year EV-to-EBIT Range
Min: 0.7   Max: 2.2
Current: 1.4

0.7
2.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.70
SNTA's Price/Net Cash is ranked higher than
56% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. SNTA: 7.70 )
SNTA' s 10-Year Price/Net Cash Range
Min: 8.58   Max: 18.68
Current: 7.7

8.58
18.68
Price/Net Current Asset Value 7.70
SNTA's Price/Net Current Asset Value is ranked higher than
65% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. SNTA: 7.70 )
SNTA' s 10-Year Price/Net Current Asset Value Range
Min: 8.58   Max: 18.68
Current: 7.7

8.58
18.68
Price/Tangible Book 7.10
SNTA's Price/Tangible Book is ranked lower than
65% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. SNTA: 7.10 )
SNTA' s 10-Year Price/Tangible Book Range
Min: 6.93   Max: 15.57
Current: 7.1

6.93
15.57
Price/Median PS Value 0.90
SNTA's Price/Median PS Value is ranked higher than
78% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. SNTA: 0.90 )
SNTA' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 1.61
Current: 0.9

0.04
1.61
Forward Rate of Return (Yacktman) -12.88
SNTA's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. SNTA: -12.88 )
SNTA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -48.2   Max: -17.2
Current: -12.88

-48.2
-17.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:YDO.Germany
Synta Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing & commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions like cancer and chronic inflammatory diseases.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide